Shopping Cart
Research status · COPD · PRP
PRP in COPD: current research and clinical findings
Initial clinical observations and preclinical data are available on PRP in chronic obstructive pulmonary disease. They contain positive signals, but are not yet sufficient to reliably determine benefit, safety or an appropriate treatment protocol.
What has been reported
Individual cohorts and case series reported changes in symptoms, quality of life and lung function.
What remains unclear
Control groups, standardised protocols and robust randomised COPD trials are still lacking.
How to interpret this
The findings are relevant for research, but do not constitute confirmed evidence of efficacy.
Starting point
Why PRP is being studied in pulmonary research
Chronic obstructive pulmonary disease is associated with persistent inflammatory processes and structural changes in the airways. Because platelets release various growth factors and signalling molecules, researchers are investigating whether platelet-rich preparations could influence inflammatory modulation or tissue repair.
This biological rationale is plausible, but it does not yet answer the clinical question. A possible mechanism does not automatically mean that PRP reduces symptoms, improves lung function or alters the course of COPD.
Important distinction
PRP is currently discussed as an experimental research approach in COPD. It should not be presented as though it were already an established standard treatment.
2023 review article
What clinical signals have been described?
The review by Knight and Kacker assessed 15 publications on PRP in chronic respiratory disease. For COPD, it relies mainly on uncontrolled cohort studies and case series.
419patients
Observations on symptoms and quality of life
In a prospective cohort, lower CCQ scores were reported after intravenous PRP administration. This indicates more favourable self-reported outcomes for symptoms, mental well-being and functional health.
- No untreated or placebo-controlled comparison group
- Spirometric follow-up in only 150 participants
- A causal PRP effect therefore cannot be determined with certainty
281patients
Observations on lung function
Another cohort reported small changes in FEV1 values after three and twelve months, respectively. The authors interpreted this as an indication of possible improvement.
- Before-and-after comparison without a control group
- No blinding and no randomisation
- The clinical significance of the measured changes remains unclear
568patients
Case series with several treatment groups
A retrospective case series reported better self-reported symptom and quality-of-life scores. However, the groups received different protocols.
- Some participants received repeated PRP applications
- One group also received bone marrow treatment
- No controlled separation of the effects of individual therapies
What supports further research
- Several studies report findings in the same positive direction.
- Symptoms, quality of life and individual lung function values were assessed.
- Preclinical studies provide possible biological explanations.
What argues against premature conclusions
- The relevant COPD data do not come from randomised controlled trials.
- Concomitant treatments, natural variation and selection bias may influence the results.
- Preparation, dose, activation and route of administration are not standardised.
Methodological assessment
An observed difference is not yet proof of an effect
Before-and-after data can provide relevant indications. Without a suitable control group, however, it remains unclear what caused a change. In addition to the intervention, concomitant treatments, motivation, measurement variability, regression to the mean or selective follow-up may also play a role.
The review authors themselves rate the COPD cohorts as low-quality evidence. Their overall positive conclusion should therefore be understood as a hypothesis that requires testing in controlled trials.
Biological plausibility
present
Preclinical data
initial indications
Clinical observations
uncontrolled
Confirmed efficacy
not established
Further data
Animal models and other lung diseases
The review also includes laboratory studies, animal models and research in other indications. These include models after partial lung resection, amiodarone-induced pulmonary fibrosis, smoke inhalation injury, COVID-19-related ARDS and airway disease in horses.
Several of these studies report inflammatory-modulating or regenerative signals. However, they do not directly answer whether PRP is effective in people with COPD. Acute lung injury, postoperative healing and experimental airway disease in animals differ substantially from COPD in cause, course and treatment.
TransferabilityResults from animal models are used to generate hypotheses, not to demonstrate clinical efficacy.
Relevance to the indicationData on ARDS, smoke inhalation or fibrosis are not automatically COPD data.
AdministrationThe publications described different routes, including intravenous, intrabronchial and nebulised administration.
PreparationsPRP, activated PRP and platelet lysate cannot simply be treated as equivalent.
Safety and standardisation
The route of administration also remains unresolved
The term “autologous” describes the origin of the starting material, but does not replace an assessment of quality and safety. For any potential use in COPD, preparation, sterility, composition, dosage and route of administration would need to be clearly defined.
The COPD studies described in the review used intravenous infusions. Other publications investigated intrabronchial or nebulised administration. At present, these data do not establish a uniform clinical protocol.
- No standardised PRP composition for COPD
- No established dose or treatment frequency
- No robust assessment of the long-term safety profile
- No basis for replacing established COPD measures
Balanced assessment
What can currently be stated responsibly?
There are initial positive clinical observations on PRP in COPD. Uncontrolled cohorts and case series have reported changes in lung function, symptoms and quality of life. These findings are scientifically relevant and should not be overlooked.
At the same time, the study designs available so far do not allow a reliable conclusion as to whether PRP caused the observed changes. Controlled COPD-specific human studies are needed to assess benefits, risks, suitable preparations and routes of administration reliably.
Has PRP been proven effective in COPD?
No. There are positive signals from observational studies and case series, but no robust randomised and controlled COPD-specific evidence of efficacy.
Are the results available so far still relevant?
Yes. They indicate which endpoints could be examined in future studies and provide a basis for further research. However, their evidential value is limited by the study designs.
Can conclusions about COPD be drawn from animal or ARDS studies?
Only to a very limited extent. Such data can indicate possible mechanisms, but they do not replace controlled studies in people with COPD.
Why is no specific application protocol described?
Because preparation, dose, frequency and route of administration have not been standardised or adequately assessed in clinical studies. A specific protocol would go beyond the available evidence.
Evidence base
- Knight AD, Kacker S. Platelet-Rich Plasma Treatment for Chronic Respiratory Disease. Cureus. 2023;15(1):e33265. DOI: 10.7759/cureus.33265.
- The COPD cohorts and case series discussed in this article are evaluated as primary sources in this review. Participant numbers and study designs have been summarised from the information presented there.
This article provides factual information on the current state of research. It does not constitute individual medical advice, diagnosis or a treatment recommendation. Existing COPD treatment should not be changed or discontinued because of experimental approaches. Editorial review status: July 2026.